Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | HCK | P08631 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17974717 | 0.79 | L3MBTL1 (0.40) | NUDT1L3MBTL1TNKSPIK3CG | |
| SCHEMBL16628943 | 0.76 | NUDT1 (0.52) | NUDT1L3MBTL1 | |
| SCHEMBL17718274 | 0.76 | NUDT1 (0.47) | NUDT1L3MBTL1TNKS | |
| SCHEMBL19646347 | 0.76 | NUDT1 (0.47) | NUDT1L3MBTL1ADORA2APIK3CDABL1 | |
| SCHEMBL16664208 | 0.72 | HTT (0.49) | NOS3NOS2 | |
| SCHEMBL16212794 | 0.72 | NUDT1 (0.52) | NUDT1L3MBTL1NOS3NOS2TNKS | |
| SCHEMBL23942101 | 0.72 | PIK3CG (0.36) | NUDT1L3MBTL1PIK3CG | |
| SCHEMBL5496407 | 0.71 | NUDT1 (0.56) | NUDT1NOS3NOS2PIK3CG | |
| SCHEMBL17657179 | 0.71 | NUDT1 (0.46) | NUDT1PIK3CDPIK3CG | |
| SCHEMBL278145 | 0.69 | NUDT1 (1.00) | NUDT1L3MBTL1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-9828377-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9775844-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9751888-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751888-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-9359365-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NUDT1 869/4885L3MBTL1 4198/4885NOS3 1630/4885 |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NUDT1 869/4885L3MBTL1 4198/4885NOS3 1630/4885 |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NUDT1 869/4885L3MBTL1 4198/4885NOS3 1630/4885 |
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NUDT1 869/4885L3MBTL1 4198/4885NOS3 1630/4885 |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NUDT1 869/4885L3MBTL1 4198/4885NOS3 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.